Merck - SCC100 - SCC100, MCF-7/S0.5 Human Breast Cancer Cell Line MCF-7/S0.5 is a tamoxifen-sensitive cell line established from the MCF-7 human breast cancer cell line by adaption to growth in low serum conditions.

ITEM #: 11569537
Estrogen receptor-positive breast cancer is the most common type of breast cancer. About 80% of all breast cancers e x press the estrogen receptor (ER+) and depend on estrogen to support the growth and spread of the cancer cells. Hormonal therapy, such as tamo x ifen, may help slow or stop the growth of ER+ breast cancers by blocking the actions of estrogen. Primary or acquired tamo x ifen resistance poses a major clinical challenge in the treatment of ER+ breast cancer. The MCF-7/S0.5 is the parental line from which many tamo x ifen-resistant cell lines have been derived and is utilized as a parental control to its derivative cell lines in parallel e x presence of hormones in the serum required in tissue culture media complicates the demonstration of specific hormone and antihormone effects. The MCF-7/S0.5 human breast cancer cells have been adapted to long-term growth in low serum concentration (0.5% fetal bovine serum) by a stepwise reduction of the medium serum content from 5% to 0.5% FBS. MCF-7/S0.5 cells e x press both estrogen and progesterone receptors and are sensitive to tamo x ifen.
Synonyms: MCF7 S0.5 Human breast cancer cell line
Application: This product is intended for sale and sold solely to academic institutions for internal academic research use per the terms of the “Academic Use Agreement” as detailed in the product documentation. For information regarding any other use, please contact licensing@ .
Other Notes: Concentration: Please refer to lot specific datasheet.
SCC100, MCF-7/S0.5 Human Breast Cancer Cell Line MCF-7/S0.5 is a tamoxifen-sensitive cell line established from the MCF-7 human breast cancer cell line by adaption to growth in low serum conditions.
This listing is for Each